IRLAB therapeutics AB reports topline results from its Phase I SAD and MAD study with IRL752 and enters into an agreement with Clinical Trial Consultants (CTC) for the planned Phase II study in Parkinson disease dementia.

March 16, 2017

For details see the Investors Relations menu above and the press release in Swedish.